Follow Spyre Therapeutics to never miss an important update.
Spyre shared a split update alongside its quarterly results. Its lead drug for inflammatory bowel disease, SPY003, showed positive early data, meaning all three of its main bowel disease treatments have now passed the initial test to show they work as intended. The company is now moving faster than planned to test these drugs in combination, with results expected by late 2027.
However, the company will stop developing SPY072 for rheumatic diseases like rheumatoid arthritis and psoriatic arthritis. While the drug was safe, it did not show a large enough benefit to justify moving forward. This narrows the company's focus back toward its core bowel disease pipeline. Spyre ended the quarter with a loss of $0.94 per share, slightly wider than the $0.79 loss analysts expected, but it remains well-funded with over $400 million in new cash raised.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
On October 5, Spyre entered an agreement to sell roughly 4.1 million shares of common stock at $85.00 per share. This sale is expected to bring in about $350 million in gross proceeds before fees.
For a biotech company with no revenue, these cash raises are the lifeblood of the business. Spyre plans to use the money to keep its clinical trials running, prepare for the final phase of testing, and start manufacturing its drug candidates. While selling new shares dilutes current owners by giving them a smaller piece of the company, it provides the necessary runway to reach the next round of trial results without running out of cash.
Source: 8-K filing
Spyre has missed its targets in three of the last four quarters, showing that management is struggling to predict the high costs of running several drug trials at once.
Follow Spyre Therapeutics to get the latest and most important updates.
Follow SYRE